Skip to main content
. 2023 Dec 28;16(1):156. doi: 10.3390/cancers16010156

Figure 2.

Figure 2

Forest plots for EFS between neoadjuvant chemoimmunotherapy and chemotherapy regimens in resected NSCLC patients.